Join 60 Degrees Pharmaceuticals' Live Investor Webinar: Advancing Tafenoquine for Babesiosis While Expanding ARAKODA(R) Commercialization

60 Degrees Pharmaceuticals Announces Partnership with The University of Southern Mississippi to Evaluate Castanospermine in Nonclinical Models of Alpha-Gal Syndrome

60 Degrees Pharmaceutical Enters Sponsored Research Agreement With University Of Southern Mississippi To Assess The Potential Of Castanospermine In Nonclinical Models Of Alpha-Gal Syndrome

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

After-Hours Market Movers for Oct. 27, 2026: Gainers and Losers

60 Degrees Pharmaceuticals Announces Clinical Improvement and Negative PCR Results in All Completed Expanded Access Babesiosis Study Patients

All five patients reported improvement; a sensitive post-treatment test found no parasite in four.

60 Degrees Pharma Reports Clinical, Molecular Results From First Five Completed Patients In Relapsing Babesiosis Expanded Access Study; All Five Completed Patients Report Clinical Improvement

60 Degrees Pharmaceuticals Sets January 2027 Babesiosis Data Readout and Plans FDA Pre-sNDA Meeting

There are notable gap-ups and gap-downs in today's session.

60 Degrees Pharmaceuticals Plans January 2027 Hospitalized Babesiosis Data Readout; Will Seek Pre-sNDA Meeting with FDA

60 Degrees Pharmaceuticals Will Conclude Enrollment In Study Of Tafenoquine In Patients Hospitalized With Severe Babesiosis And Proceed With Unblinding; Primary And Secondary Endpoint Results Are Expected In January 2027

60 Degrees Pharmaceuticals Shares Rise 12.5% Premarket - 60 Degrees (NASDAQ:SXTP)

SXTP Stock Whipsaws As Traders Study Deep Red Financials

SXTP Stock Grinds Higher As Traders Track Volatile Price Action